Keryx KRX-101 interim Phase II data

KERX said interim data from 120 patients showed that 24% of those given 200 or 400 mg of KRX-101 (sulodexide) in a Phase II trial to treat diabetic nephropathy met the primary endpoint of therapeutic ...